Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I study of subcutaneous BRIUMVI in relapsing multiple sclerosis

Next Previous
Trial Profile

A Phase I study of subcutaneous BRIUMVI in relapsing multiple sclerosis

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ublituximab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use

Most Recent Events

  • 06 Aug 2024 According to a TG Therapeutics Inc media release, the first has been patients dosed in this study.
  • 06 Aug 2024 According to a TG Therapeutics Inc media release, the company has initiated phase 1 study in RMS patients for subcutaneous ublituximab and received FDA IND clearance to study azer-cel (allogeneic CD19 CAR-T) in patients with progressive MS.
  • 06 Aug 2024 Status changed from planning to recruiting, according to a TG Therapeutics Inc media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top